Company Overview and News
KUALA LUMPUR (Aug 30): The FBM KLCI opened higher before falling as investors took cue from US stocks' overnight rise and evaluated Malaysian corporate earnings.
4863 5183 PECGF MYTEF BSMAF 1818
KUALA LUMPUR (Aug 27): The Minority Shareholder Watch Group (MSWG) will include financially distressed companies and China-based companies listed on Bursa Malaysia on its radar by June next year, from 300 listed firms currently.
MLYNF 7113 8621 TPGVF AMMHF 1023 5347 TNABY SMEBF AXXTF MYTEF PNAGF 5183 MLYBY PECGF 4197 6399 5681 6033 CIMDF TGLVY 1155 PNADF 4588 1015 4863 6888 TNABF BSMAF 1818
KUALA LUMPUR: The chemical manufacturing unit of Petroliam Nasional Bhd (Petronas) is actively looking to acquire companies to expand its specialty chemical business, its chief executive officer said.
RDS.B 5183 RDS.A PECGF XOM RYDBF RDSB RDSA RYDAF
KUALA LUMPUR (Aug 20): Based on corporate announcements and news flow today, companies that will be in focus on Thursday (Aug 23) may include: Sime Darby Plantation Bhd, Petronas Chemicals Group Bhd, Eastern & Oriental Bhd, MCT Bhd, Taliworks Corp, Ranhill Holdings Bhd, Versatile Creative Bhd, AMMB Holdings Bhd, Sunway Bhd and Paramount Corp Bhd.
4995 1015 5183 PECGF AMMHF 5272
KUALA LUMPUR (Aug 21): The chemical manufacturing unit of Malaysia's state energy firm Petronas is actively looking to acquire companies to expand its specialty chemical business, its chief executive officer said on Tuesday.
RDS.B 5183 RDS.A PECGF XOM RYDBF RDSB RDSA RYDAF
Deputy Minister of International Trade & Industry, Dr Ong Kian Ming and Petronas president & group CEO Tan Sri Wan Zulkiflee Wan Ariffin at the launch of Petronas Chemicals Group Bhd (PCG) 10 new product brands.
KUALA LUMPUR (Aug 21): Shares of Petronas Chemicals Group Bhd, Petronas Gas Bhd and Petronas Dagangan Bhd rose among Bursa Malaysia's top gainers today after these companies reported higher second quarter net profit from a year earlier and declared dividends.
PNADF 5183 PECGF 5681 BSMAF PNAGF 6033 1818
KUALA LUMPUR (Aug 21): The FBM KLCI opened higher today as Petronas-linked stocks rose among Bursa Malaysia top gainers. Globally, China-US trade sentiment and Turkey's geopolitical and economic concerns continue to dictate financial markets' direction.
5183 PECGF BSMAF 1818
KUALA LUMPUR (Aug 20): Malaysian stocks started the week on a positive note, as selected heavyweight counters like Petronas Chemicals Group Bhd, Axiata Group Bhd and DiGi.Com Bhd lifted the benchmark FBM KLCI up 4.11 points or 0.23% despite negative market breadth.
6084 5183 6888 PECGF 1899 UPBMF 5032 AXXTF 2836 2089
KUALA LUMPUR (Aug 20): Petronas Chemicals Group Bhd is currently monitoring the impact of the escalating trade war between the United States and China on the petrochemical industry.
Petronas Chemicals Group Bhd (Aug 16, RM9.24) Maintain buy with a higher target price (TP) of RM11.23: Petronas Chemicals Group Bhd (PetChem) booked RM2.6 billion in first half of financial year 2018 (1HFY18) core profit (+14% year-on-year [y-o-y]). The stronger profit was primarily on higher plant utilisation at the fertiliser and methanol (F&M) wing and stronger product prices. The olefins and derivatives (O&D) division is likely to remain stable in 2018, with strong oil prices providing support for product prices while methanol prices are likely to firm on a potential supply shortage.
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
17h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
19h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET